METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outsmart tough cancers that resist standard treatment
Disease control Recruiting nowThis study is testing whether combining two drugs, cabozantinib and nivolumab, can help control advanced melanoma or head and neck cancer that has worsened despite standard immunotherapy. It will enroll about 150 adults whose cancer has progressed on prior treatment. A key goal i…
Matched conditions: METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Cholesterol drug may boost cancer treatment in new trial
Disease control Recruiting nowThis study is testing whether adding the common cholesterol-lowering drug lovastatin to the immunotherapy drug pembrolizumab can better control head and neck cancer that has returned or spread. Researchers believe lovastatin may make cancer cells more vulnerable to the immune sys…
Matched conditions: METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Doctors test custom vaccine to fight returning head and neck cancer
Disease control Recruiting nowThis early-stage study is testing a personalized vaccine made from a patient's own tumor cells. It aims to see if the vaccine, given alone or with an immunotherapy drug (pembrolizumab), is safe and can help the immune system fight advanced head and neck cancer that has returned o…
Matched conditions: METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for Tough-to-Treat head and neck cancers: can a drug duo outperform the standard?
Disease control Recruiting nowThis study is for people with advanced head and neck cancer that has returned or spread and has stopped responding to standard platinum-based chemotherapy. It aims to see if combining two immunotherapy drugs (pembrolizumab and cetuximab) helps patients live longer than using pemb…
Matched conditions: METASTATIC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC